List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 53 studies with search of: Amyloidosis | Open Studies
Include studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Condition: Primary Systemic AL Amyloidosis
Intervention: Drug: Lenalidomide, Dexamethasone and Cyclophosphamide
2 Recruiting Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
3 Recruiting Study of Systemic Amyloidosis Presentation and Prognosis
Condition: Amyloidosis
Intervention:
4 Recruiting Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-Diagnosed Light-Chain (AL)-Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
5 Recruiting The Effect of Diflunisal on Familial Amyloidosis
Conditions: Familial Amyloid Polyneuropathy;   Familial Amyloidosis
Interventions: Drug: diflunisal;   Other: placebo
6 Recruiting A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
7 Recruiting Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
8 Recruiting Transthyretin-Associated Amyloidoses Outcomes Survey (THAOS)
Condition: TTR-associated Amyloidosis
Intervention: Other: THAOS is a noninterventional patient registry
9 Recruiting High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
10 Recruiting Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone
11 Recruiting A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Conditions: Leukemia;   Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
12 Recruiting Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis
Conditions: Familial Amyloid Polyneuropathy;   ATTR-PN
Intervention: Drug: Fx-1006A
13 Recruiting Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: melphalan
14 Recruiting Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: therapeutic immune globulin;   Other: laboratory biomarker analysis
15 Recruiting Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: dexamethasone;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
16 Recruiting Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
17 Recruiting Second Autologous Stem Cell Transplant in Treating Patients With Persistent or Recurrent Primary Systemic (AL) Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
18 Recruiting Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: bortezomib;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
19 Recruiting Collecting Samples From Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: clonality analysis;   Genetic: polymerase chain reaction;   Genetic: protein analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis;   Procedure: fluorescence spectroscopy;   Procedure: quality-of-life assessment
20 Recruiting Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Conditions: Multiple Myeloma;   Primary Amyloidosis
Interventions: Drug: Melphalan;   Procedure: Stem Cell Infusion;   Behavioral: Questionnaires;   Drug: Granulocyte-colony stimulating factor (G-CSF);   Procedure: Apheresis

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services